Symbols / FENC Stock $7.18 +6.85% Fennec Pharmaceuticals Inc.

Healthcare • Biotechnology • United States • NCM
FENC (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Jeffrey S. Hackman
Exch · Country NCM · United States
Market Cap 249.24M
Enterprise Value 210.74M
Income -9.74M
Sales 44.64M
FCF (ttm) -7.33M
Book/sh 1.04
Cash/sh 1.07
Employees 35
Insider 10d —
IPO Sep 15, 2017
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 7.99
PEG 1.47
P/S 5.58
P/B 6.92
P/C —
EV/EBITDA -34.10
EV/Sales 4.72
Quick Ratio 5.71
Current Ratio 6.37
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.34
EPS next Y 0.90
EPS Growth —
Revenue Growth 73.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-12
Earnings (prior) 2026-03-24
ROA -6.80%
ROE -65.82%
ROIC —
Gross Margin 91.57%
Oper. Margin -18.54%
Profit Margin -21.82%
Shs Outstand 34.71M
Shs Float 16.86M
Insider Own 14.38%
Instit Own 53.55%
Short Float 3.11%
Short Ratio 3.72
Short Interest 930.61K
52W High 9.92
vs 52W High -27.62%
52W Low 5.65
vs 52W Low 27.08%
Beta 0.91
Impl. Vol. 8.86%
Rel Volume 1.42
Avg Volume 169.74K
Volume 240.80K
Target (mean) $15.17
Tgt Median $15.50
Tgt Low $13.00
Tgt High $18.00
# Analysts 6
Recom Strong_buy
Prev Close $6.72
Price $7.18
Change 6.85%
About

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$15.17
Mean price target
2. Current target
$7.18
Latest analyst target
3. DCF / Fair value
$-3.80
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.18
Low
$13.00
High
$18.00
Mean
$15.17

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-16 reit Wedbush Outperform → Outperform $13
2026-01-09 init Piper Sandler — → Overweight $18
2025-08-21 reit HC Wainwright & Co. Buy → Buy $13
2025-08-15 main Craig-Hallum Buy → Buy $14
2025-05-20 reit HC Wainwright & Co. Buy → Buy $13
2025-05-14 main Craig-Hallum Buy → Buy $13
2025-03-11 reit HC Wainwright & Co. Buy → Buy $13
2024-12-17 reit HC Wainwright & Co. Buy → Buy $13
2024-08-22 main HC Wainwright & Co. Buy → Buy $13
2024-08-14 main Craig-Hallum Buy → Buy $15
2024-05-15 main Craig-Hallum Buy → Buy $17
2024-05-15 main HC Wainwright & Co. Buy → Buy $15
2024-04-04 main HC Wainwright & Co. Buy → Buy $18
2024-03-18 main Craig-Hallum Buy → Buy $18
2023-08-04 main HC Wainwright & Co. Buy → Buy $17
2023-06-21 reit HC Wainwright & Co. Buy → Buy $18
2023-04-06 main Cantor Fitzgerald — → Overweight $16
2023-04-04 reit HC Wainwright & Co. — → Buy $18
2023-03-31 reit HC Wainwright & Co. — → Buy $18
2023-01-26 reit HC Wainwright & Co. — → Buy $18
News
RSS: Latest FENC news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-01 RAYKOV ROSTISLAV CHRISTOV Director — 10,781 $6.47 $69,753
2026-05-01 RAYKOV ROSTISLAV CHRISTOV Director — 18,376 $2.45 $38,215
2026-04-30 ANDRADE ROBERT C Chief Financial Officer — 1,703 — —
2026-04-30 HACKMAN JEFFREY S Chief Executive Officer — 1,159 — —
2026-04-30 CIOFFI CHRISTIANA MARIE Officer — 155 — —
2026-04-30 EVANS TERRY L Officer — 168 — —
2026-04-30 SAYAD PIERRE SARGIS PH.D. Officer — 168 — —
2026-04-01 RAYKOV ROSTISLAV CHRISTOV Director — 10,946 $6.31 $69,069
2026-04-01 RAYKOV ROSTISLAV CHRISTOV Director — 15,598 $2.45 $38,215
2026-03-31 RAYKOV ROSTISLAV CHRISTOV Director — 5,208 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
44.64
-6.09%
47.54
+123.69%
21.25
+1284.50%
1.53
Operating Revenue
44.64
-6.09%
47.54
+123.69%
21.25
+1284.50%
1.53
Cost Of Revenue
3.76
+18.22%
3.18
+152.90%
1.26
+1363.95%
0.09
Reconciled Cost Of Revenue
3.73
+50.63%
2.47
+59.96%
1.55
+1697.67%
0.09
Gross Profit
40.88
-7.84%
44.35
+121.85%
19.99
+1279.78%
1.45
Operating Expense
47.22
+12.77%
41.88
+26.70%
33.05
+36.65%
24.19
Research And Development
0.25
-18.57%
0.31
+448.21%
0.06
-98.41%
3.53
Selling General And Administration
46.91
+13.09%
41.48
+26.82%
32.71
+59.50%
20.51
Selling And Marketing Expense
18.62
+1.03%
18.43
+51.99%
12.12
+335.30%
2.79
General And Administrative Expense
28.29
+22.73%
23.05
+11.99%
20.59
+16.16%
17.72
Other Gand A
28.29
+22.73%
23.05
+11.99%
20.59
+16.16%
17.72
Total Expenses
50.99
+13.16%
45.06
+31.33%
34.31
+41.35%
24.27
Operating Income
-6.35
-355.99%
2.48
+118.98%
-13.06
+42.57%
-22.74
Total Operating Income As Reported
-6.28
-344.63%
2.57
+120.11%
-12.77
+43.46%
-22.59
EBITDA
-7.45
-255.31%
4.80
+138.81%
-12.36
+45.26%
-22.59
Normalized EBITDA
-5.46
-209.98%
4.96
+140.24%
-12.33
+44.94%
-22.39
Reconciled Depreciation
0.10
-87.13%
0.80
0.00
-100.00%
0.15
EBIT
-7.55
-288.97%
4.00
+131.60%
-12.65
+44.36%
-22.74
Total Unusual Items
-2.00
-1124.54%
-0.16
-379.41%
-0.03
+82.38%
-0.19
Total Unusual Items Excluding Goodwill
-2.00
-1124.54%
-0.16
-379.41%
-0.03
+82.38%
-0.19
Special Income Charges
-2.02
0.00
—
—
Other Special Charges
2.02
—
—
—
Net Income
-9.74
-2134.17%
-0.44
+97.28%
-16.05
+32.34%
-23.71
Pretax Income
-9.63
-13470.42%
-0.07
+99.56%
-16.05
+32.34%
-23.71
Net Non Operating Interest Income Expense
-1.29
+45.83%
-2.39
+19.17%
-2.95
-277.14%
-0.78
Interest Expense Non Operating
2.08
-48.88%
4.07
+19.89%
3.39
+247.03%
0.98
Net Interest Income
-1.29
+45.83%
-2.39
+19.17%
-2.95
-277.14%
-0.78
Interest Expense
2.08
-48.88%
4.07
+19.89%
3.39
+247.03%
0.98
Interest Income Non Operating
0.79
-53.21%
1.68
+281.41%
0.44
+126.15%
0.20
Interest Income
0.79
-53.21%
1.68
+281.41%
0.44
+126.15%
0.20
Other Income Expense
-2.00
-1124.54%
-0.16
-379.41%
-0.03
+82.38%
-0.19
Gain On Sale Of Security
0.03
+115.95%
-0.16
-379.41%
-0.03
+82.38%
-0.19
Tax Provision
0.11
-70.96%
0.36
0.00
—
Tax Rate For Calcs
0.00
+0.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
-0.42
-1124.54%
-0.03
0.00
0.00
Net Income Including Noncontrolling Interests
-9.74
-2134.17%
-0.44
+97.28%
-16.05
+32.34%
-23.71
Net Income From Continuing Operation Net Minority Interest
-9.74
-2134.17%
-0.44
+97.28%
-16.05
+32.34%
-23.71
Net Income From Continuing And Discontinued Operation
-9.74
-2134.17%
-0.44
+97.28%
-16.05
+32.34%
-23.71
Net Income Continuous Operations
-9.74
-2134.17%
-0.44
+97.28%
-16.05
+32.34%
-23.71
Normalized Income
-8.16
-2557.34%
-0.31
+98.08%
-16.01
+31.93%
-23.52
Net Income Common Stockholders
-9.74
-2134.17%
-0.44
+97.28%
-16.05
+32.34%
-23.71
Diluted EPS
-0.34
0.00
+100.00%
-0.60
+33.33%
-0.90
Basic EPS
-0.34
0.00
+100.00%
-0.60
+33.33%
-0.90
Basic Average Shares
28.58
+4.70%
27.29
+2.71%
26.57
+1.14%
26.27
Diluted Average Shares
28.58
+4.70%
27.29
+2.71%
26.57
+1.14%
26.27
Diluted NI Availto Com Stockholders
-9.74
-2134.17%
-0.44
+97.28%
-16.05
+32.34%
-23.71
Amortization
0.06
-28.09%
0.09
-68.99%
0.29
+92.62%
0.15
Amortization Of Intangibles Income Statement
0.06
-28.09%
0.09
-68.99%
0.29
+92.62%
0.15
Depreciation Amortization Depletion Income Statement
0.06
-28.09%
0.09
-68.99%
0.29
+92.62%
0.15
Depreciation And Amortization In Income Statement
0.06
-28.09%
0.09
-68.99%
0.29
+92.62%
0.15
Total Other Finance Cost
—
0.09
-68.99%
0.29
+92.62%
0.15
Line Item Trend 2023-12-31
Total Assets
26.86
Current Assets
26.86
Cash Cash Equivalents And Short Term Investments
13.27
Cash And Cash Equivalents
13.27
Receivables
8.81
Accounts Receivable
8.81
Gross Accounts Receivable
—
Allowance For Doubtful Accounts Receivable
—
Inventory
2.16
Prepaid Assets
2.58
Other Current Assets
0.04
Total Non Current Assets
0.01
Non Current Accounts Receivable
—
Non Current Deferred Assets
0.01
Other Non Current Assets
0.01
Current Liabilities
7.55
Payables And Accrued Expenses
7.53
Payables
3.78
Accounts Payable
3.78
Current Accrued Expenses
3.75
Current Debt And Capital Lease Obligation
0.02
Current Capital Lease Obligation
0.02
Current Deferred Liabilities
0.00
Current Deferred Revenue
0.00
Total Non Current Liabilities Net Minority Interest
30.93
Long Term Debt And Capital Lease Obligation
30.93
Long Term Debt
30.93
Long Term Capital Lease Obligation
0.00
Non Current Deferred Liabilities
0.00
Non Current Deferred Revenue
0.00
Stockholders Equity
-11.62
Common Stock Equity
-11.62
Capital Stock
144.31
Common Stock
144.31
Share Issued
27.03
Ordinary Shares Number
27.03
Treasury Shares Number
0.00
Additional Paid In Capital
62.07
Retained Earnings
-219.25
Gains Losses Not Affecting Retained Earnings
1.24
Other Equity Adjustments
1.24
Total Equity Gross Minority Interest
-11.62
Total Capitalization
19.31
Working Capital
19.30
Invested Capital
19.31
Total Debt
30.95
Net Debt
17.66
Capital Lease Obligations
0.02
Net Tangible Assets
-11.62
Tangible Book Value
-11.62
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-12.47
-146.23%
26.98
+257.38%
-17.14
+5.07%
-18.06
Cash Flow From Continuing Operating Activities
-12.47
-146.23%
26.98
+257.38%
-17.14
+5.07%
-18.06
Net Income From Continuing Operations
-9.74
-2134.17%
-0.44
+97.28%
-16.05
+32.34%
-23.71
Depreciation Amortization Depletion
0.10
-87.13%
0.80
0.00
—
Amortization Cash Flow
0.10
-87.13%
0.80
0.00
—
Depreciation And Amortization
0.10
-87.13%
0.80
0.00
—
Amortization Of Intangibles
0.10
-87.13%
0.80
0.00
—
Other Non Cash Items
-2.73
-1391.94%
0.21
-26.48%
0.29
+1.77%
0.28
Stock Based Compensation
7.03
+38.96%
5.06
-5.47%
5.35
+31.00%
4.09
Provisionand Write Offof Assets
2.88
-33.43%
4.32
0.00
—
Operating Gains Losses
2.02
—
—
—
Unrealized Gain Loss On Investment Securities
0.00
-97.53%
0.08
+107.69%
0.04
-78.80%
0.18
Change In Working Capital
-12.04
-171.07%
16.94
+349.97%
-6.78
-714.51%
1.10
Change In Receivables
-12.44
-58.01%
-7.87
-8.31%
-7.27
-370.49%
-1.54
Changes In Account Receivables
-12.44
-58.01%
-7.87
-8.31%
-7.27
-370.49%
-1.54
Change In Inventory
-1.28
-320.73%
0.58
+136.65%
-1.58
-174.31%
-0.58
Change In Prepaid Assets
-0.66
-30.30%
-0.51
-585.58%
0.10
-60.61%
0.26
Change In Payables And Accrued Expense
3.60
+517.27%
-0.86
-143.94%
1.96
-33.51%
2.95
Change In Accrued Expense
2.21
+776.99%
-0.33
-156.60%
0.58
-57.08%
1.34
Change In Payable
1.39
+359.59%
-0.54
-138.69%
1.39
-13.90%
1.61
Change In Account Payable
1.39
+359.59%
-0.54
-138.69%
1.39
-13.90%
1.61
Change In Other Working Capital
—
24.81
—
—
Change In Other Current Assets
-1.27
-259.17%
0.80
+26433.33%
0.00
-50.00%
0.01
Financing Cash Flow
22.63
+266.19%
-13.62
-305.11%
6.64
-67.98%
20.73
Cash Flow From Continuing Financing Activities
22.63
+266.19%
-13.62
-305.11%
6.64
-67.98%
20.73
Net Issuance Payments Of Debt
-19.48
-49.82%
-13.00
-360.16%
5.00
-74.93%
19.93
Issuance Of Debt
—
—
5.00
-79.96%
24.93
Repayment Of Debt
-19.48
-49.82%
-13.00
0.00
+100.00%
-5.00
Long Term Debt Issuance
—
—
5.00
-79.96%
24.93
Long Term Debt Payments
-19.48
-49.82%
-13.00
0.00
+100.00%
-5.00
Net Long Term Debt Issuance
-19.48
-49.82%
-13.00
-360.16%
5.00
-74.93%
19.93
Net Common Stock Issuance
42.05
0.00
—
—
Proceeds From Stock Option Exercised
2.19
+68.33%
1.30
-24.18%
1.72
+84.91%
0.93
Net Other Financing Charges
-2.13
-11.43%
-1.92
-2454.67%
-0.07
+42.75%
-0.13
Changes In Cash
10.15
-24.03%
13.37
+227.23%
-10.51
-492.86%
2.67
Beginning Cash Position
26.63
+100.72%
13.27
-44.19%
23.77
+12.67%
21.10
End Cash Position
36.79
+38.12%
26.63
+100.72%
13.27
-44.19%
23.77
Free Cash Flow
-12.47
-146.23%
26.98
+257.38%
-17.14
+5.07%
-18.06
Interest Paid Supplemental Data
4.16
+8.87%
3.82
—
—
Income Tax Paid Supplemental Data
0.75
0.00
—
—
Common Stock Issuance
42.05
0.00
—
—
Issuance Of Capital Stock
42.05
0.00
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category